

TECHNICAL SPECIFICATIONS

Drug / Excipient	Periferinis balionas, dengtas Sirolimu
Drug	Sirolimus
Drug Dose	1.27 µg/mm ²
Drug Carrier	Phospholipid
Sirolimo dozė ne mažiau 1,27 mikrogramai kvadratiniam mm; Sirolimas sujungtas su fosfolipidiniu ar analogišku nešikliu.	
Balloon	
Delivery System	Ištūmimo sistema OTW („per vielą“) 0,018“ ir 0,035“ vieloms
Balloon Compliance	Over The Wire
Sheath Compatibility	Semi-Compliant
Guiding Catheter Compatibility	4F to 7F
No. of folds	5F to 9F
	3 & 6
Balionas turi būti suspaustas ne mažiau, kaip per 6 klostes	

GUIDEWIRE COMPATIBILITY

Guidewire Diameter (mm)	Balloon Diameter (mm)	Balloon Length (mm)	Catheter Shaft Length (cm)
0.014"	2.00, 2.50, 3.00, 3.50, 4.00	40, 60, 80, 100, 120, 150, 200	90, 120, 150
0.018"	2.00, 2.50, 3.00, 3.50, 4.00, 5.00, 5.50, 6.00, 7.00	40, 60, 80, 100, 120, 150, 200	90, 120, 150
0.035"	3.00, 4.00, 5.00, 6.00, 7.00, 8.00, 9.00, 10.00, 12.00	20, 40, 60, 80, 100, 120, 150, 200	130, 150

Baliono diametru intervalas turi būti ne mažesnis nei nuo mm iki 12 mm


Baliono ilgių intervalas turi būti ne mažesnis nei nuocm iki 20 cm

Kateterio ilgai turi apimti ne mažesnj intervalą nuo cm iki 150 cm

For Ordering information visit website: www.conceptmedical.com

Tinkami naudoti per 4 Fr introduiserį ir 5 Fr kateterį nukreipikį

OTW DELIVERY SYSTEM



Turi būti mažiau 2 rentgenokontrastinės žymės

*The above diagram is just an illustration of the product.

Disclaimer: The law restricts these devices to sale by or on the order of a physician. Indications, contradictions, warnings can be found in the product labelling / IFU supplied with each device. For restricted use only in countries where product is registered with applicable health authorities.



Concept Medical

f t i n /conceptmedicals

info@conceptmedical.com

www.conceptmedical.com

Scan for more details



CB.BA.MP.BRO.ver.2.0.z1-02

Concept Medical

MagicTouch PTA

SIROLIMUS COATED PTA BALLOON CATHETER

Periferinis balionas, dengtas Sirolimu

SIROLIMUS
PERIPHERAL ARTERY DISEASE

MAGICTOUCH PTA

Magic Touch PTA designed with proprietary Nanolute Technology is intended for percutaneous transluminal angioplasty of de-novo, stenotic and in-stent restenotic lesions in Superficial femoral (SFA), popliteal, Below The Knee (BTK) and iliac arteries.

PRIMARY PATENCY AT 6 MONTHS




PRIMARY PATENCY AT 12 MONTHS



Presented at TCT CONNECT 2020 & LINC 2021 by Dr. Edward Choke
Patients treated with Magic Touch PTA had **Rutherford scores 5 & 6** and WIFI score 4-8.

UNIQUE COATING TECHNOLOGY

Magic Touch PTA is developed with Nanolute Technology which possesses unique circumferential coating technology that facilitates homogeneous drug distribution to target lesions



COATING

Circumferential Coating is performed under Low Pressure inflation leading to 100% surface area coating.



REFOLDING

3 or 6 folds




INFLATION

Homogeneous Drug Delivery due to Circumferential Coating

WHY SIROLIMUS?

Attribute	Paclitaxel	Sirolimus
Drug Nature	Cytotoxic	Cytostatic
Drug Therapeutic Range	Narrow	Wide
Margin of Safety	100 fold	10,000 Fold
Tissue Absorption	Fast	Slow
Tissue Retention	Long	Short

NANOLUTE TECHNOLOGY




ADVANTAGES OF NANOLUTE TECHNOLOGY

- Facilitates better adhesion of Sirolimus on the balloon surface
- Effective drug transfer to the deepest layer of the vessel
- Circumferential coating ensures homogeneous drug delivery
- Better in-tissue bioavailability of Sirolimus

SIROLIMUS DISTRIBUTION STUDY

DTF labelled Sirolimus was used to assess the drug distribution following DCB treatment*



A: Adventitia; EEL: External Elastic Lamina; IEL: Internal Elastic Lamina; L: Lumen; M: Media *EuroIntervention. 2013 May 20;9(1): 148-56